Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Tatsuhiro Ogami Last modified date:2019.06.19



Graduate School


Phone
092-642-5394
Fax
092-642-5414
Academic Degree
MD-PhD
Country of degree conferring institution (Overseas)
No
Field of Specialization
Obstetrics & Gynecology
ORCID(Open Researcher and Contributor ID)
0000-0002-3086-012X
Total Priod of education and research career in the foreign country
00years00months
Research
Research Interests
  • Gastrointestinal perforation during treatment with bevacizumab combined with cytotoxic chemotherapy for ovarian cancer patients.
    keyword : bevacizumab, gastrointestinal perforation
    2019.01.
  • Deep vein thrombosis in gynecologic cancer patients under treatment
    keyword : deep vein thrombosis, gynecologic cancer, pulmonary embolism
    2017.04.
  • Renal protective effect of magnesium sulfate in gynecologic cancer patients during cisplatin-containing chemotherapy
    keyword : renal protection, magnesium, cisplatin
    2016.04.
  • Comparison of radiotherapy and systemic chemotherapy as a postoperative adjuvant therapy for cervical cancer
    keyword : Cervical cancer, Radiotherapy, Systemic chemotherapy, adjuvant therapy
    2015.04.
  • Analysis of the effects and mechansms of pazopanib against stem-like cells of uterine carcinoma and carcinosarcoma.
    keyword : uterine carcinoma, uterine carcinosarcoma, stem-like cell, pazopanib
    2013.04~2018.03.
Academic Activities
Reports
1. Tatsuhiro Ogami, Kiyoko Kato, Pathogenesis of endometrial cancer, Current Approaches to Endometrial Cancer, Future science group , 2014.11, Endometrial cancer is the most common form of cancer of the female genital reproductive tract, with 150,000 new cases diagnosed each year worldwide. More than 90% of endometrial cancers are sporadic and the remaining hereditary. Sporadic cases are categorized clinicopathologically as estrogen-dependent endometrioid endometrial carcinomas (type I) and non-endometrioid endometrial carcinomas (type II). With molecular genetic developments, the pathogenesis of sporadic and hereditary endometrial carcinomas has gradually been elucidated, and the pathogenic mechanisms are reviewed in this chapter with respect to types I and II. In addition, new evidence regarding cancer stem cells in endometrial carcinomas, the existence of which was recently reported, is introduced here..
Presentations
1. Tatsuhiro Ogami, Hiroshi Yagi, Yasunaga Masafumi, Ichiro Onoyama, Yoshiaki Kawano, Kaneki Eisuke, Okugawa Kaoru, Hideaki Yahata, Kenzo Sonoda, Kiyoko Kato, Renal protective effect of magnesium sulfate in gynecologic cancer patients during cisplatin-containing chemotherapy, 第68回日本産科婦人科学会, 2016.04, [Objective]Nephrotoxicity is diagnosed in 28-42% of patients applied cisplatin. Mg2+ is involved in active transport of cisplatin in proximal tubule cells, therefore, we retrospectively examined whether Mg2+ supplementation prevent nephrotoxicity during cisplatin-containing chemotherapy. All patients provided written informed consent before treatment.
[Methods]Forty four patients of gynecologic cancer treated in our hospital from Oct 2014 to Sep 2015(study group)were analyzed. They were supplied magnesium sulfate containing 8mEq of Mg2+ just before cisplatin administration. Serum creatinine level(Cr:mg/dL)and glomerular filtration rate(GFR:mL/min)were examined before and after treatment. These laboratory data were compared with those of 74 patients treated previously without Mg2+ supplementation(control group).
[Results]Statistically significant Cr elevation(+0.11±0.17 vs -0.03±0.10)and GFR decrease(-13.0±22.2 vs+2.2±17.6)were found in control group compared with study group(p<0.001). Discontinuation of chemotherapy occurred in 8 cases in control group due to renal dysfunction. However, all patients in study group could receive scheduled treatment.
[Conclusion]Magnesium sulfate supplementation might be effective for renal protection during cisplatin-containing chemotherapy..
2. Comparison of radiotherapy and systemic chemotherapy as a postoperative adjuvant therapy for cervical cancer.